Skip to search boxSkip to navigationSkip to main content

Cortical Excitability Before and After Long-Term Perampanel Treatment for Epilepsy

  • Robert M. Helling
    ,
  • ,
  • Prisca R. Bauer
    ,
  • Roland D. Thijs
    ,
  • Josemir W. Sander
    ,
  • Machiel Zwarts
*Corresponding author for this work
Output:
Contribution to journal
Article
Academic
Peer-review

Open access

Information

Output type

Output:
Contribution to journal
Article
Academic
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1256-1264 (9 pages)

Journal (Volume, Issue Number)

Annals of Clinical and Translational Neurology (Volume 12, Issue 6)

Publication milestones

  • E-pub ahead of print - 17/04/2025
  • Published - 06/2025

Publication status

Published - 06/2025

ISSN

2328-9503

Funding Details

Funding: The perampanel manufacturer Eisai provided an unrestricted grant to support this study. We thank S. Shmuely, M. Demuru, E. Geertsema, and T. Punte for helping with the measurements. We want to acknowledge W. M. Stern for helping set up the measurement protocol and S. N. Kalitzin for helping with the hardware and software. J.W.S. is based at UCLH/UCL Comprehensive Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centre's funding scheme. He receives support from the Dr. Marvin Weil Epilepsy Research Fund, the Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie, the UK Epilepsy Society, the National Institute of Health Research, and the Academy of Medical Sciences. R.M.H. and R.D.T. receive support from the Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie. R.D.T. reports lecture and consultancy fees from Medtronic, UCB, Theravarance, Zogenix, Novartis, and Arvelle and grants from EpilepsieNL, Medtronic, Michael J Fox Foundation, NewLife Wearables, and the Netherlands Organisation for Health Research and Development (843002707). P.R.B. receives lecture fees from NovoCure and Aurikamed. J.W.S. reports personal fees from Eisai, UCB Pharma, and Angelini Pharma and grants from Angelini and UCB to his department outside the submitted work. G.H.V. reports grants from the Dutch National Epilepsy Fund and Eisai. All other authors have no disclosures to make. We thank S. Shmuely, M. Demuru, E. Geertsema, and T. Punte for helping with the measurements. We want to acknowledge W. M. Stern for helping set up the measurement protocol and S. N. Kalitzin for helping with the hardware and software. J.W.S. is based at UCLH/UCL Comprehensive Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centre's funding scheme. He receives support from the Dr. Marvin Weil Epilepsy Research Fund, the Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie, the UK Epilepsy Society, the National Institute of Health Research, and the Academy of Medical Sciences. R.M.H. and R.D.T. receive support from the Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie.
FundersFunding number
NIHR
-
ZonMw : Dutch Organisation for Health Research and Development
843002707

Abstract

<p>Objective: Antiseizure medications (ASMs), which may influence cortical excitability, are the mainstay of epilepsy treatment. Transcranial magnetic stimulation (TMS) helps evaluate cortical excitability. We assessed changes in TMS responses using serial TMS measurements in people treated with an adjunctive noncompetitive AMPA-receptor antagonist. Methods: We included adults with refractory, active epilepsy (≥ 1 seizure/month), advised to start adjunctive treatment with the noncompetitive AMPA-receptor antagonist perampanel as outpatients. After informed consent, we performed TMS measurement at three points: baseline before starting perampanel, at around 2 months after starting (4 mg/day), and at a final/effective dose around 6 months. Dependent on seizure reduction (> 50%), participants were dichotomized into responders (Rs) and nonresponders (NRs). We compared changes in motor cortex excitability through the rMT using a linear mixed-effects model. We evaluated TMS-evoked potentials (TEPs) to single pulse and paired pulse using within-subject Monte Carlo–based permutation analysis. Results: We included 18 adults, of whom 17 (6 R, 11 NR, 1 lost to follow-up) had baseline and second-month measurements, and nine (4 R, 5 NR) had all three. In responders, motor cortex excitability, quantified by rMT, significantly increased with increasing dose. Conversely, no significant changes were seen in the NR subgroup. TEPs for the single pulse and paired pulse showed no significant clusters for any peaks between measurement and group comparisons. Interpretation: The TEPs showed no significant changes between measurements and/or groups. Motor cortex excitability quantified by rMT is a potential biomarker to track or predict treatment outcomes in people starting adjunctive perampanel for epilepsy.</p>

Metrics

Metrics

Download statistics
Download count
62
Scopus
citations
1
SciVal
citations
1
SciVal
FWCI
0.30
SciVal
Author count
7
SciVal
Paper percentile
46

PlumX, opens in new tab

Captures
8
Citation count
1